Tesamorelin
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
A stabilized GHRH analog, FDA-approved to reduce visceral fat in HIV lipodystrophy, used off-label for fat loss, lipid gains, and GH restoration. Evidence is strong for those effects, muscle gains are modest, and cognitive benefit is only weakly supported. Injections often cause site reactions and joint aches, effects reverse once stopped, and a theoretical cancer risk from IGF-1 is unresolved. FDA-approved, though longevity use is off-label.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Egrifta (tesamorelin) is a synthetic 44-amino-acid version of growth hormone-releasing hormone (GHRH), the natural signal your brain sends to the pituitary gland to produce growth hormone. It has a chemical modification that protects it from being broken down too quickly in the body. Tesamorelin is the only FDA-approved medication specifically for reducing excess abdominal fat (lipodystrophy) in people living with HIV.
How it works in the body
A stabilized GHRH analog with a trans-3-hexenoic acid modification. It activates GHRH receptors on pituitary somatotrophs, producing physiological GH pulses. Specifically targeted at visceral adipose tissue — the deep abdominal fat linked to metabolic disease — reducing it without affecting subcutaneous fat or limb fat.
Research overview
Tesamorelin works by binding to GHRH receptors on the pituitary gland, stimulating your body's own natural pulsatile growth hormone release rather than replacing it with synthetic GH. This preserves the brain's normal feedback loop, which is a significant advantage over direct growth hormone injection. Clinical studies showed an 81% increase in IGF-1 levels (a marker of growth hormone activity). It is the only US-approved medication for HIV-associated lipodystrophy and has been extensively studied in Phase III trials. In the longevity space, it is of interest because it stimulates endogenous GH release, but it still carries risks from GH and IGF-1 elevation, including glucose intolerance and fluid retention. Its FDA approval is limited to the HIV indication.
Who researches Tesamorelin?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching visceral fat reduction
One of the primary studied benefits of Tesamorelin.
Important considerations for
Those with Active malignancy
AbsoluteFDA label: discontinue if active malignancy develops. GH promotes tumor growth.
Those who are pregnant or breastfeeding
AbsoluteFDA label: can cause fetal harm based on mechanism of action.
Those with Disruption of hypothalamic-pituitary axis from surgery/radiation
HighMay not work if pituitary is damaged — requires functional somatotrophs.
Those with Diabetic retinopathy
HighGH elevation can worsen proliferative retinopathy.
Safety & interactions
Do not use if
Active malignancy
AbsoluteFDA label: discontinue if active malignancy develops. GH promotes tumor growth.
Disruption of hypothalamic-pituitary axis from surgery/radiation
HighMay not work if pituitary is damaged — requires functional somatotrophs.
Diabetic retinopathy
HighGH elevation can worsen proliferative retinopathy.
General cautions
Pregnancy
AbsoluteFDA label: can cause fetal harm based on mechanism of action.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
Injection site reactions (most common)
HighEGRIFTA SV FDA label, Adverse Reactions; PMID 31611038
Arthralgia, pain in extremities, peripheral edema, myalgia
ModerateEGRIFTA SV FDA label, Warnings (Fluid Retention) and Adverse Reactions; PMID 18057338
50% develop anti-tesamorelin antibodies (no apparent efficacy impact)
LowEGRIFTA SV FDA label, Immunogenicity
Increased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.
ModerateEGRIFTA SV FDA label, Warnings (Glucose Intolerance and Diabetes Mellitus); PMID 31611038
Effects reverse upon cessation — requires ongoing treatment
HighPMID 20554713; EGRIFTA SV FDA label
Theoretical cancer risk with long-term GH/IGF-1 elevation
TheoreticalEGRIFTA SV FDA label, Warnings (Neoplasms)
Contraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis
HighEGRIFTA SV FDA label, Contraindications
Interaction summary(8)
Rated by direction with this peptide
Insulin and oral antidiabetic agents (metformin, sulfonylureas, etc.)
CautionModerateGH-induced insulin resistance can raise glucose and HbA1c (5% vs 1% reaching HbA1c >=6.5%; HR 3.3 for incident diabetes), potentially requiring antidiabetic dose escalation and mandating glucose monitoring in treated patients.
EGRIFTA SV FDA label, Warnings/Drug Interactions
Glucocorticoid replacement therapy (hydrocortisone, prednisone) in hypoadrenalism
CautionModerateGH inhibits 11-beta-hydroxysteroid dehydrogenase type 1, reducing conversion of cortisone to cortisol, so patients on glucocorticoid replacement may need their replacement or stress glucocorticoid doses increased to avoid adrenal insufficiency. This interaction is explicitly stated on the EGRIFTA SV label.
EGRIFTA SV FDA label, Drug Interactions
CYP450-metabolized drugs (cyclosporine, anticonvulsants, corticosteroids, sex steroids)
CautionLowThe EGRIFTA label carries only a generic recommendation to monitor for potential CYP450 interactions, with no quantified clinical effect demonstrated for tesamorelin specifically (it is an inferred GH class effect). Plasma levels of narrow-therapeutic-index substrates could theoretically shift, so clinical monitoring rather than a fixed dose adjustment is advised.
EGRIFTA SV FDA label, Drug Interactions
Somatropin (exogenous GH) and other GH secretagogues (e.g. ipamorelin, CJC-1295, MK-677)
CautionTheoreticalCombining with another agent that raises GH/IGF-1 offers no studied additive benefit and would compound the shared dose-dependent risks of fluid retention, arthralgia, insulin resistance, and IGF-1 elevation; no combination trials exist.
Mechanism-based; no clinical data (class effects per EGRIFTA SV and somatropin labels)
Simvastatin and other statins used for HIV-associated dyslipidemia
SynergisticLowTesamorelin's triglyceride and cholesterol:HDL improvements were observed in phase 3 populations that already included substantial statin use, so the lipid benefit appears additive to and independent of statin therapy - though this is inferred from the trial population composition rather than a prespecified statin-interaction analysis. CYP-mediated statin level shifts remain a theoretical reason for routine monitoring.
PMID 18057338; PMID 20554713 (inferred from population; no dedicated statin-interaction study)
Antiretroviral therapy (protease inhibitors, NRTIs)
NeutralLowTesamorelin was developed and trialed in patients on stable combination ART with no clinically significant pharmacokinetic interaction identified and no loss of virologic control; it does not correct ART-associated lipoatrophy of subcutaneous fat.
PMID 18057338; PMID 20554713; EGRIFTA SV FDA label
GLP-1 receptor agonists (semaglutide, tirzepatide)
ProtectiveTheoreticalCo-administration is mechanistically attractive because GLP-1 agonists improve insulin sensitivity and could offset tesamorelin's glycemic penalty while both reduce hepatic fat, but no trial has tested the combination and the interaction remains speculative.
Mechanism-based; no clinical trial data
Levothyroxine / thyroid hormone replacement
CautionTheoreticalGH excess increases peripheral T4-to-T3 conversion and can unmask latent central hypothyroidism, a documented somatropin class effect that has not been specifically demonstrated for tesamorelin; periodic thyroid function checks are reasonable in replaced patients.
GH class effect (somatropin labeling); not established for tesamorelin
Known risks(7)
Injection site reactions (most common)
Arthralgia, pain in extremities, peripheral edema, myalgia
50% develop anti-tesamorelin antibodies (no apparent efficacy impact)
Increased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.
Effects reverse upon cessation — requires ongoing treatment
Theoretical cancer risk with long-term GH/IGF-1 elevation
Contraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis
Drug interactions(3)
Cortisone/glucocorticoids
Glucocorticoids suppress GH secretion and may reduce tesamorelin efficacy
Exogenous HGH
Both elevate GH/IGF-1. Combining risks supraphysiologic levels.
CJC-1295
Both are GHRH analogs. Tesamorelin is FDA-approved with stronger evidence base.
Research & benefits
Evidence base
- Evidence Level
- Level 1 — FDA Approved
- Total Studies
- 30
- Human Participants
- 1500
Two pivotal Phase III RCTs (n=806 combined) led to FDA approval 2010. Additional RCTs for NAFLD, muscle composition, cognition. 2026 meta-analysis of 5 RCTs confirmed efficacy. Long-term data to 52 weeks.
Researched for(8)
Rated by confidence in the evidence
Visceral fat reduction
HighFDA-approved indication, confirmed in two large phase 3 RCTs in HIV lipodystrophy.
PMID 18057338 (N Engl J Med 2007;357:2359-70); PMID 20554713 (J Clin Endocrinol Metab 2010)
Lipid improvement
HighSignificant triglyceride and cholesterol ratio improvements in RCTs, though LDL unchanged.
PMID 18057338; PMID 20554713
Liver fat/NAFLD
HighReduced liver fat and fibrosis progression in a 12-month RCT, limited to HIV cohorts.
PMID 31611038 (Lancet HIV 2019;6:e821-30); PMID 25038357 (JAMA 2014;312:380-9)
Muscle composition
MediumModest lean mass gains shown in RCTs, but no proven gains in strength or function.
PMID 18057338; PMID 20554713
Cognitive function
LowSingle small RCT in older/MCI adults suggested benefit; preliminary, never replicated.
PMID 22869065 (Arch Neurol 2012;69:1420-9)
Physiologic GH restoration
HighRCTs confirm pulsatile GH-driven IGF-1 rise; long-term outcome edge over GH untested.
PMID 20554713; EGRIFTA SV FDA label (DailyMed setid 3d783378-b02d-4f19-99dd-0fc91a042224)
Body image/QoL
HighPrespecified RCT patient-reported outcome improved in HIV lipodystrophy; not tested in healthy adults.
PMID 20554713
Fat quality
SpeculativeImproved fat quality is plausible but based on small substudies, not a powered trial.
Extrapolated from PMID 31611038 (fibrosis progression) and small substudy/transcriptomic reports; no dedicated powered RCT
Benefits(8)
Visceral fat reduction
Lipid improvement
Liver fat/NAFLD
Muscle composition
Cognitive function
Physiologic GH restoration
Body image/QoL
Fat quality
Key studies(5)
Falutz J et al.
NEJM
2007
-15.2% VAT, triglycerides -50mg/dL in 412 patients
Falutz J et al.
J Clin Endocrinol Metab
2010
Sustained VAT/lipid reduction, IGF-1 +81% over 52 weeks in 806 patients
Baker LD et al.
Arch Neurol
2012
Improved executive function, with a nonsignificant verbal-memory trend, in 152 adults aged 55-87.
Stanley TL et al.
Lancet HIV
2019
-37% hepatic fat, attenuated fibrosis progression over 12 months
Multiple
Obes Res Clin Pract
2026
Confirmed: VAT -27.71cm2, lean mass +1.42kg, hepatic fat reduction
What research suggests over time
Weeks 2-4
FDA registration trialsIGF-1 levels rise; subjective energy and sleep quality improvements reported.
Months 2-3
Falutz et al. NEJM 2007Visceral adipose tissue (VAT) reduction begins; trunk fat measurably lower on imaging.
Long-term
Phase 3 RCT~15-18% VAT reduction at 26 weeks in HIV lipodystrophy trials; effects regress on discontinuation.
Prescribing labels
FDA-Approved Labels
This page does not list doses. Each product below has an FDA label with its prescribing information.
- Protocol
- Egrifta WR (tesamorelin)
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
Monitoring & labs
Baseline before starting, then per marker schedule during protocol.
Baseline labs(6)
Complete Blood Count (CBC)
Optimal All markers within mid-rangeEstablishes baseline for detecting hematological changes.
Lab normal Standard reference ranges
Comprehensive Metabolic Panel (CMP)
Optimal Liver enzymes <25, glucose 75–90, eGFR >90Liver and kidney function baseline.
Lab normal Standard reference ranges
IGF-1
Optimal 150–250 ng/mL (adults)Direct marker of growth hormone axis activity — essential for tracking GH peptide effects.
Lab normal Age-dependent (~80–280 ng/mL)
Fasting glucose + HbA1c
Optimal 75–90 mg/dLGH peptides can affect insulin sensitivity and glucose metabolism.
Lab normal 65–99 mg/dL
Fasting insulin
Optimal 2–6 μIU/mLEnables HOMA-IR calculation — GH peptides can reduce insulin sensitivity.
Lab normal 2.6–24.9 μIU/mL
Lipid panel
Optimal ApoB <80, TG <80, HDL >55GH affects lipid metabolism; baseline needed to track changes.
Lab normal TC <200, LDL <100, HDL >40, TG <150
Ongoing tracking(3)
IGF-1
Every 6-8 weeksOptimal 150–250 ng/mL (adults)Track growth hormone axis response — primary efficacy marker.
Lab normal Age-dependent (~80–280 ng/mL)
Fasting glucose
Every 4-8 weeksOptimal 75–90 mg/dLGH peptides can reduce insulin sensitivity.
Lab normal 65–99 mg/dL
Liver enzymes (ALT/AST)
Every 8 weeksOptimal ALT & AST under 25 U/LHepatic monitoring during GH axis stimulation.
Lab normal ALT 7–56, AST 10–40 U/L
Retest schedule(6)
Baseline
critical
Before starting
Full baseline + IGF-1, fasting glucose, fasting insulin, lipid panel.
Early follow-up
critical
Week 4
Recheck IGF-1, fasting glucose, HbA1c. GH peptides commonly affect glucose handling.
Second check
critical
Week 8
Recheck IGF-1 trajectory and metabolic markers.
Mid-protocol
critical
Week 12
Comprehensive retest. IGF-1 should be in target range (150–250 ng/mL).
Ongoing
standard
Every 6-8 weeks
Sustained monitoring of IGF-1 and metabolic markers.
Post-protocol
standard
4-6 weeks after stopping
Confirm IGF-1 returns toward baseline.
When to stop and reassess(5)
ALT or AST
stopAbove 2× upper limit of normal (>~80 U/L)
Stop protocol and consult a provider — possible drug-induced liver injury.
eGFR
stopDrop of >15 mL/min/1.73m² from baseline, or below 60
Stop protocol and consult a provider — possible kidney function decline.
Symptoms
stopNew severe symptoms correlating with lab changes
Stop protocol and seek medical evaluation immediately.
IGF-1
stopAbove 350 ng/mL
Stop or reduce dose — sustained elevation carries theoretical cancer and cardiovascular risk.
Fasting glucose
consultConsistently above 100 mg/dL (or HbA1c rising >0.3%)
Consult a provider — GH peptides commonly reduce insulin sensitivity.
Lab monitoring helps track your body's response to Tesamorelin. Any unexplained changes should prompt discussion with your prescribing provider.
Regulation & availability
Why researchers look at it
Across 1,500+ trial patients, tesamorelin has shown benefits well beyond its FDA-approved use for HIV-related abdominal fat: improved lipids and reduced liver fat in HIV cohorts, plus preliminary cognitive findings in older adults. The 2026 five-RCT meta-analysis evaluated HIV-related body composition and metabolic outcomes, not cognition. Unlike direct GH injection, it preserves the brain's natural pulsatile release and feedback loop. Ongoing research in non-HIV populations could make it the preferred approach to age-related GH decline.
- Estimated cost
- About $11,030 per 28-day kit at the US cash price (Egrifta WR, Drugs.com price guide, checked 2 Nov 2026); insurance covers the approved HIV indication
- FDA status
- FDA-approved 2010 (Egrifta). Egrifta WR approved March 2025 (weekly preparation). Only FDA-approved medication for HIV lipodystrophy. Manufactured by Theratechnologies.
- WADA status
- Banned — GH secretagogue / GHRH analog under prohibited substances
- Prescribability
- FDA-approved as Egrifta SV/WR for excess abdominal fat in adults with HIV-associated lipodystrophy. Off-label prescribing is permitted. Tesamorelin is a biologic and is not eligible for 503A or 503B compounding exemptions.
- Availability
- FDA-approved Egrifta SV/WR (WR approved March 2025). Prescription treatment for excess abdominal fat in adults with HIV-associated lipodystrophy; off-label prescribing is permitted. Tesamorelin is a biologic and does not qualify for 503A or 503B compounding exemptions.
International status
EU
Not EMA-approved
US
FDA-approved (Egrifta)
Canada
Previously Health Canada-approved; current Egrifta records are cancelled: DIN 02438712 is Cancelled Post Market and DIN 02423677 is Cancelled Pre Market.
Regulatory timeline(2)
- 2010FDA approvalEgrifta approved for HIV lipodystrophy
- 2025-03Egrifta WR approvedNew formulation prepared once weekly
Sources & FAQs
Research sources(5)
Frequently asked questions(4)
How does it work?
Stimulates pituitary to produce GH in natural pulsatile pattern. Preserves feedback loops unlike exogenous GH.
Time to results?
4-6 weeks initial changes. 3-6 months for significant body composition improvements.
Side effects?
Injection site reactions, arthralgia, peripheral edema, myalgia. 50% develop antibodies (no efficacy impact). Modest HbA1c risk.
Only for HIV?
FDA-approved only for HIV lipodystrophy. Off-label use for NAFLD, cognitive decline, anti-aging. Insurance rarely covers off-label.